HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment
HIV infection has a significant impact on the natural history of chronic hepatitis B virus (HBV)
infection, with increased levels of HBV DNA, accelerated progression of liver disease and …
infection, with increased levels of HBV DNA, accelerated progression of liver disease and …
[HTML][HTML] KASL clinical practice guidelines for management of chronic hepatitis B
Korean Association for the Study of the … - Clinical and …, 2019 - ncbi.nlm.nih.gov
Diseases (AASLD) also presented and continued to revise their clinical practice guidelines,
and the latest updates were in 2015, 2017, and 2018. However, since the medical …
and the latest updates were in 2015, 2017, and 2018. However, since the medical …
[HTML][HTML] Guidelines for prevention and treatment of chronic hepatitis B
G Wang, Z Duan - Journal of clinical and translational hepatology, 2021 - ncbi.nlm.nih.gov
To achieve the goal of the World Health Organization to eliminate viral hepatitis as a major
public health threat by 2030, the Chinese Society of Infectious Diseases and the Chinese …
public health threat by 2030, the Chinese Society of Infectious Diseases and the Chinese …
慢性乙型肝炎防治指南(2019 年版).
王贵强， 段钟平 - Journal of Clinical Hepatology/Linchuang …, 2019 - search.ebscohost.com
中华医学会感染病学分会,中华医学会肝病学分会 Page 1 +,-. 慢性乙型肝炎防治指南(2019 年版
) 中华医学会感染病学分会,中华医学会肝病学分会 摘要:为了实现世界卫生组织提出的“2030 年 …
) 中华医学会感染病学分会,中华医学会肝病学分会 摘要:为了实现世界卫生组织提出的“2030 年 …
APASL guidance on stopping nucleos (t) ide analogues in chronic hepatitis B patients
Chronic hepatitis B virus (HBV) infection is currently incurable. Long-term treatment with
potent and safe nucleos (t) ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) …
potent and safe nucleos (t) ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) …
Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients
Background & Aims Tenofovir disoproxil fumarate (TDF) is one the most potent nucleot (s)
ide analogues for treating chronic hepatitis B virus (HBV) infection. Phenotypic resistance …
ide analogues for treating chronic hepatitis B virus (HBV) infection. Phenotypic resistance …
Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate
KS Byun, J Choi, JH Kim, YS Lee, HC Lee… - Clinical …, 2022 - Elsevier
Background & Aims It remains unknown whether tenofovir alafenamide (TAF) could replace
tenofovir disoproxil fumarate (TDF) in patients with drug-resistant hepatitis B virus (HBV) …
tenofovir disoproxil fumarate (TDF) in patients with drug-resistant hepatitis B virus (HBV) …
Management of hepatitis B virus infection: 2018 guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and …
Hepatitis B virus (HBV) infection is an important public health problem in Canada. In keeping
with evolving evidence and understanding of HBV pathogenesis, the Canadian Association …
with evolving evidence and understanding of HBV pathogenesis, the Canadian Association …
The risk of hepatocellular carcinoma among chronic hepatitis B virus‐infected patients outside current treatment criteria
We assessed the incidence of hepatocellular carcinoma (HCC) in those outside of current
treatment recommendations and risk factors associated with HCC development. A multi …
treatment recommendations and risk factors associated with HCC development. A multi …
New antivirals for the treatment of chronic hepatitis B
V Soriano, P Barreiro, L Benitez, JM Peña… - Expert opinion on …, 2017 - Taylor & Francis
Introduction: Current treatment with oral nucleos (t) ides entecavir or tenofovir provide
sustained suppression of HBV replication and clinical benefit in most chronic hepatitis B …
sustained suppression of HBV replication and clinical benefit in most chronic hepatitis B …